AAM Announces 2018 Board of Directors
ORLANDO, FL (February 12, 2018) —The Association for Accessible Medicines (AAM) announced the election of its 2018 Board of Directors and Executive Committee today, at its 2018 Annual Meeting. Apotex President and Chief Operating Officer Jeff Watson is the 2018 AAM Chair of the Board. AAM also named Robert Stewart, President, Amneal, as Vice-Chairman of […]
AAM Continues to Build Its State Government Affairs Team
WASHINGTON DC (NOVEMBER 6, 2017) – Brett Michelin and Ashlie Van Meter are joining the Association for Accessible Medicines’ (AAM) State Government Affairs team as Director and Senior Director, respectively. “We are excited to welcome Ashlie and Brett to the AAM team,” says Carrie Hartgen, Vice President, State Government Affairs. “The depth and breadth of their […]
Five Reasons to Attend the 2017 FallTech Conference
Generic medicines represent nearly 90 percent of all prescriptions written in the United States, but only 26 percent of the costs, saving patients and payers nearly $5 billion every week. Keeping these life-saving medicines available to patients is a national priority. Every year, more than 700 generics industry professionals gather at FallTech 2017 to share […]
Kristin Murphy Joins AAM – Michael Brzica Promoted to Vice President
WASHINGTON DC (JULY 17, 2017) – Today, Kristin Murphy joins the Association for Accessible Medicines (AAM) as Director of Federal Affairs. Also, effective today, Michael Brzica has been promoted to Vice President, Federal Government Affairs. Prior to joining AAM, Kristin was part of the legislative affairs team at the Ambulatory Surgery Center Association (ASCA). Over the […]
Rachel Sher Joins Association for Accessible Medicines
WASHINGTON DC (JULY 10, 2017) – Today, Rachel Sher joins the Association for Accessible Medicines (AAM) as Deputy General Counsel. Prior to joining AAM, Rachel served as a Senior Policy Analyst in the Commissioner’s Office of Policy at the Food and Drug Administration (FDA). In that capacity, she acted as the FDA lead in the […]
